TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

Lawrence Eichenfield, MD, outlines a patient-centered approach to atopic dermatitis, assessing disease history, life impact, and prior therapy use.

The global atopic dermatitis market size was valued at USD 6.62 billion in 2025 and is predicted to hit around USD 12.97 billion by 2034, rising at a 7.75% CAGR, a study published by Towards ...

Children with food allergies who had late- vs. early-onset atopic dermatitis faced significantly lower odds for multiple food allergies, according to results published in Annals of Allergy, Asthma & ...

A cohort study finds the risk for acne in patients on JAK inhibitors for atopic dermatitis was about 2.5 times greater than ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity ...

Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...

The ADHAND trial has demonstrated that tralokinumab significantly improved skin clarity, itch, and pain in adults with moderate-to-severe hand atopic dermatitis. All primary and secondary ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

Experts break down the most important facts about atopic dermatitis on the hands, including risk factors, treatments, and tips for soothing relief. Atopic dermatitis (AD), the most common form of ...